- Home
- RGLS vs FAAS Comparison
RGLS vs FAAS Comparison
Compare RGLS & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- FAAS
- Stock Information
- Founded
- RGLS 2007
- FAAS 2021
- Country
- RGLS United States
- FAAS Indonesia
- Employees
- RGLS N/A
- FAAS N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- FAAS
- Sector
- RGLS Health Care
- FAAS
- Exchange
- RGLS Nasdaq
- FAAS NYSE
- Market Cap
- RGLS 102.1M
- FAAS 115.9M
- IPO Year
- RGLS 2012
- FAAS N/A
- Fundamental
- Price
- RGLS $1.42
- FAAS $0.54
- Analyst Decision
- RGLS Strong Buy
- FAAS
- Analyst Count
- RGLS 6
- FAAS 0
- Target Price
- RGLS $10.33
- FAAS N/A
- AVG Volume (30 Days)
- RGLS 493.3K
- FAAS 268.9K
- Earning Date
- RGLS 11-07-2024
- FAAS 09-17-2024
- Dividend Yield
- RGLS N/A
- FAAS N/A
- EPS Growth
- RGLS N/A
- FAAS N/A
- EPS
- RGLS N/A
- FAAS N/A
- Revenue
- RGLS N/A
- FAAS $57,730,593.00
- Revenue This Year
- RGLS N/A
- FAAS N/A
- Revenue Next Year
- RGLS N/A
- FAAS N/A
- P/E Ratio
- RGLS N/A
- FAAS N/A
- Revenue Growth
- RGLS N/A
- FAAS 38.16
- 52 Week Low
- RGLS $1.08
- FAAS $0.52
- 52 Week High
- RGLS $3.79
- FAAS $13.99
- Technical
- Relative Strength Index (RSI)
- RGLS 41.95
- FAAS 32.18
- Support Level
- RGLS $1.36
- FAAS $0.50
- Resistance Level
- RGLS $1.65
- FAAS $0.70
- Average True Range (ATR)
- RGLS 0.10
- FAAS 0.14
- MACD
- RGLS -0.01
- FAAS 0.01
- Stochastic Oscillator
- RGLS 28.57
- FAAS 8.00
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.